Bristol-Myers Squibb (NYSE:BMY) is one of the globe's top drugmakers and a staple in dividend investors' portfolios.
Big drug companies such as Bristol-Myers, Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK) offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if Bristol-Myers' dividend can be sustained following the loss of patent protection on the company's top-selling drug Plavix two years ago and in light of billions more in at-risk revenue tied to future patent expirations.
In the following slideshow you'll see whether I think Bristol's dividend is safe and gain insight into how Bristol-Myers matches up with industry peers.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.